Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of androgen deprivation (AD) +/- cixutumumab, in new metastatic hormone-sensitive prostate cancer (mHSPC).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Fred Hutch Cancer Center, Huntsman Cancer Institute, University of Washington, Comprehensive Cancer Centers of Nevada, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, The University of Texas at San Antonio Health Science Center, USC Norris Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W3006738998